Earnings call transcript: Sagility lifts margin outlook in Q2 2026

Sagility’s fiscal Q2 revenue rose 22.5% year over year to INR 20,321 million ($212.6 million), while adjusted EBITDA increased 23% to INR 5,353 million and its margin reached a six-quarter high of 26.3%. The company raised FY 2027 adjusted EBITDA margin guidance to 25%–26% from 24%–25%, and reported a net cash position of INR 1,127 million; shares were up 2.21% at $45.39. Sagility closed its $20 million Chirok acquisition, with up to $12.35 million in additional consideration tied to revenue targets, while warning that open-enrollment and AEP revenue may be slightly below last year.

Analysis

Sagility — margin quality matters more than the headline growth. The constant-currency organic pace is materially less dramatic than rupee growth, while the margin upgrade is supported partly by FX and geographic mix. That makes the upgrade a near-term estimate-supporting catalyst, not yet proof of a higher structural margin ceiling: management still frames 24%–26% as the operating range and expects much of AI productivity to accrue to clients.

Over 1–3 months, the key swing factor is AEP/open-enrollment delivery. A slightly weaker season could make the low-double-digit organic growth outlook harder to sustain if steady-state demand or deal ramp timing also softens. The new payment-integrity engagement is potentially meaningful but revenue builds over time; do not capitalize its stated ACV as immediate revenue. Over 6–18 months, Chirok creates credible cross-sell and larger-deal optionality, but the provider practice is small and management has not set a measurable growth target. Verify Chirok’s customer concentration and post-close retention; its high stated margin is not evidence of realized synergies.

The contrarian risk is that this may be an operationally strong quarter with limited multiple-expansion fuel: AI could improve delivery economics but client sharing of savings constrains retained upside, while longer sales cycles defer conversion. Data quality also warrants caution: the Meta headline is unrelated, the forecast revenue is on an incompatible scale, and the transcript’s EBITDA reconciliation contains an apparent inconsistency. Validate the filing and quote before trading; the cited $45.39 price should not be treated as reliable without confirmation.

Key Decisions for Investors

• Do not chase the reported share-price move on this material alone. First reconcile the listing/quote, currency basis, actual EPS, and adjusted-to-reported EBITDA bridge against the company filing.
• Watch the next AEP/open-enrollment update and quarterly constant-currency organic growth. A season materially weaker than management’s current expectation, or a cut to organic guidance, would falsify the near-term constructive view.
• Treat Chirok as a 6–18 month option on cross-selling, not as a current earnings catalyst. Track provider growth, acquired-client retention, and larger combined RCM wins; lack of measurable progress over coming quarters weakens the thesis.
• For existing exposure, retain a modest constructive bias only while the 25%–26% margin outlook holds; reassess if margins retreat on operating execution rather than FX/mix, or if wage costs rise beyond the assumptions embedded in guidance.